PL2588090T3 - Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole - Google Patents

Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole

Info

Publication number
PL2588090T3
PL2588090T3 PL11732405T PL11732405T PL2588090T3 PL 2588090 T3 PL2588090 T3 PL 2588090T3 PL 11732405 T PL11732405 T PL 11732405T PL 11732405 T PL11732405 T PL 11732405T PL 2588090 T3 PL2588090 T3 PL 2588090T3
Authority
PL
Poland
Prior art keywords
pharmaceutically acceptable
acceptable salts
dosage forms
oral dosage
dabigatran etexilate
Prior art date
Application number
PL11732405T
Other languages
English (en)
Inventor
Vesna Kroselj
Ksela Sonja Jursa
Original Assignee
Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44628481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2588090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D., Novo Mesto
Publication of PL2588090T3 publication Critical patent/PL2588090T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11732405T 2010-07-01 2011-07-01 Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole PL2588090T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SI201000196 2010-07-01
SI201000209 2010-07-12
EP11732405.3A EP2588090B2 (en) 2010-07-01 2011-07-01 Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
PCT/EP2011/061140 WO2012001156A2 (en) 2010-07-01 2011-07-01 Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
PL2588090T3 true PL2588090T3 (pl) 2017-12-29

Family

ID=44628481

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11732405T PL2588090T3 (pl) 2010-07-01 2011-07-01 Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole

Country Status (8)

Country Link
US (1) US20130177652A1 (pl)
EP (1) EP2588090B2 (pl)
EA (1) EA022969B1 (pl)
ES (1) ES2631980T3 (pl)
PL (1) PL2588090T3 (pl)
PT (1) PT2588090T (pl)
SI (1) SI2588090T1 (pl)
WO (1) WO2012001156A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6215239B2 (ja) 2012-02-21 2017-10-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ダビガトランエテキシラートの経口医薬組成物
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015113324A1 (zh) * 2014-01-30 2015-08-06 杭州领业医药科技有限公司 达比加群酯及其盐的投药制剂及其制备方法
WO2015195990A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
WO2016016853A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Method of controlling carbamoyl impurity in pharmaceutical compositions of dabigatran
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
WO2019004980A2 (en) * 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
TR201706848A2 (tr) * 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722630A2 (pl) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
EP3787624A4 (en) * 2018-05-04 2022-03-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DABIGATRAN ETEXILATE CAPSULE IN CAPSULE COMPOSITIONS
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
EP4061369A4 (en) * 2019-11-19 2024-04-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL FORM COMPRISING AN ACIDIC SUBSTANCE
WO2023139243A1 (en) * 2022-01-21 2023-07-27 Adamed Pharma S.A A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
CN116687877B (zh) * 2023-08-07 2023-11-10 山东国邦药业有限公司 一种酒石酸泰万菌素干混悬剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CA2476054C (en) 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
CA2716642C (en) 2008-03-28 2017-02-28 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
EP2288335A1 (en) 2008-03-28 2011-03-02 Boehringer Ingelheim International GmbH Process for preparing orally administered dabigatran formulations
US8277804B2 (en) * 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
TWI436994B (zh) 2008-07-14 2014-05-11 Boehringer Ingelheim Int 製備含有達比加群（ｄａｂｉｇａｔｒａｎ）之藥物組合物的新穎方法

Also Published As

Publication number Publication date
EA022969B1 (ru) 2016-03-31
ES2631980T3 (es) 2017-09-07
EP2588090B1 (en) 2017-04-19
PT2588090T (pt) 2017-06-26
EP2588090B2 (en) 2023-11-22
WO2012001156A3 (en) 2012-08-30
US20130177652A1 (en) 2013-07-11
EA201291421A1 (ru) 2013-05-30
SI2588090T1 (sl) 2017-06-30
WO2012001156A2 (en) 2012-01-05
EP2588090A2 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
PL2588090T3 (pl) Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole
HK1200741A1 (en) Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
IL272501A (en) Oral administration forms of bendamustine and their medical use
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
HK1203832A1 (en) Oral pharmaceutical compositions of dabigatran etexilate
EP2747563A4 (en) COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
IL231485A (en) Oral dosage forms of medicinal preparations are resistant to abuse
HK1223935A1 (zh) 無定形萊特莫韋及其用於口服施用的固體藥物製劑
IL221742A (en) Oral Pharmaceuticals Containing Debigtran Etxylate
SI2400954T1 (sl) Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli
IL214420A0 (en) Pharmaceutical compositions comprising tamsulosin and solifenacin for oral administration
HK1183228A1 (zh) 口服藥物治療方法和組合物
HK1200337A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
EP2456439A4 (en) STABLE PHARMACEUTICAL OMEPRAZOLE FORMULATION FOR ORAL ADMINISTRATION
SI2654729T1 (sl) Homogene farmacevtske oralne dozirne oblike, ki obsegajo lerkanidipin in enalapril ali njune farmacevtsko sprejemljive soli skupaj z organsko kislino
HUE040419T2 (hu) Analgetikus gyógyászati kompozíció orális beadásra
EP2386301A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLOPIDINE OR PHARMACEUTICAL ACCEPTABLE SALTS AND BETA BLOCKERS, AND USE THEREOF
SI2585051T2 (sl) Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
HU0900482D0 (en) Pharmaceutical formulation for oral administration